-
Twelve cycles of single-agent paclitaxel administered to women with advanced ovarian cancer who attain a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy significantly prolongs the duration of progression-free survival.
-
Evaluations may be based on faulty assumptions; FDA, Customs finds potentially dangerous drug shipments; Color in enteral feeding tube linked to toxicity, death; Antiviral agent causes adverse effects in SARS patients
-
Fuzeon (enfuvirtide), also known as T-20, was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in March 2003. It is the first drug in a unique class of antiretrovirals, known as fusion inhibitors. Enfuvirtide is the newest development in drugs used to treat the human immunodeficiency virus (HIV-1).
-
Adverse drug reactions (ADRs) are common occurrences in hospitals. Historically, the incidence of ADRs in hospitalized patients ranges from 6% to 20%, and 3% to 7% of hospital admissions have been attributed to ADRs.
-
In the Pipeline
-
2003 Salary Survey Results
-
A study published in 1999 showed that having a pharmacist on a physician rounding team in an intensive care unit (ICU) reduced the incidence of adverse drug events (ADEs) by two-thirds.
-
Pharmacists now have another antibiotic to use in the treatment of complicated skin and skin structure infections.
-
The Food and Drug Administrations (FDAs) Counterfeit Drug Task Force has issued its interim report outlining potential options for an approach to combat counterfeit drugs.
-
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA):
